RxDoctor Payments Data

Mathew Hutchinson, MD

Clinical Cardiac Electrophysiology · Tucson, AZNPI 1255329959

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $53,059 of the $74,954 with a category attached, or 70.8%. 11 manufacturers reported payments, led by Medical Device Business Services, Inc. at 58.3% of the total. Reporting peaked in 2019 at $24,676 and has fallen 95.6% since, to $1,085 in 2025.

$74,954in general payments, 2019–2025

Across 639 payments — averaging $117.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$44K
  • Biosense Webster, Inc.$13K
  • Abbott$7K
  • Medtronic$5K
  • Atricure, Inc.$4K
  • Boston Scientific$1K
  • plus $314 from 5 others
$100,726in research payments, 2019–2025

Across 38 payments — averaging $2650.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Impulse Dynamics (USA) Inc.$57K
  • Boston Scientific$25K
  • Cardiofocus, Inc.$12K
  • Philips North America LLC$7K

What the payments were for

  • Consulting fees$53,05971%
  • Speaking & faculty fees$10,15014%
  • Travel & lodging$5,5017%
  • Food & beverage$6,2438%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,954 in reported general payments places this provider in the 80th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$229,866
Medicare patients
469
Services billed
1,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$76,565
XareltoRivaroxaban15$22,813
Flecainide Acetate44$2,130
Amiodarone Hcl40$1,317
SotalolSotalol Hcl43$1,178
Metoprolol Succinate50$746
Potassium Chloride18$440
ClopidogrelClopidogrel Bisulfate23$374
Furosemide14$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$76,56555 claims
Johnson & JohnsonXarelto$13$22,81315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →